TELA

$0.80

Post-MarketAs of Mar 17, 8:00 PM UTC

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$0.80
Potential Upside
5%
Whystock Fair Value$0.84
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$35.76M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.89
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
2.41

Recent News

Zacks
Mar 2, 2026

Astrana Health, Inc. (ASTH) Q4 Earnings and Revenues Surpass Estimates

Astrana Health, Inc. (ASTH) delivered earnings and revenue surprises of +252.25% and +2.89%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Feb 26, 2026

Anika Therapeutics (ANIK) Q4 Earnings and Revenues Beat Estimates

Anika (ANIK) delivered earnings and revenue surprises of +1,450.00% and +6.03%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Nov 14, 2025

TELA Bio Inc (TELA) Q3 2025 Earnings Call Highlights: Revenue Growth and Strategic Expansions ...

Despite achieving a new revenue milestone, TELA Bio Inc (TELA) faces profitability hurdles and revises future growth expectations.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Nov 13, 2025

TELA Bio, Inc. (TELA) Reports Q3 Loss, Misses Revenue Estimates

TELA Bio (TELA) delivered earnings and revenue surprises of -11.76% and -5.53%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Nov 12, 2025

Humacyte, Inc. (HUMA) Reports Q3 Loss, Misses Revenue Estimates

Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of +17.65% and -17.71%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

BEARISH
Negative press. News cycle fixated on risk factors or misses.